Parmax Pharma Ltd

540359

Summary

Fair Value Assessment
Fairly Valued
Fair ValueQ43.01UncertaintyVery High
Close Price41.74Mar 11, 2025
Market Closed
41.74
Price Down by |%
Previous Close
41.74
Day Range
41.74 – 43.00
Year Range
24.18 – 54.00
Bid / Ask
Market Cap
156.2 Mil
Volume / Average
14.0 / 1.1 k
Beta (5-Year)
-0.40
Shares Outstanding
3.74 Mil
Primary Exchange
Bombay Stock Exchange

Business Description
Parmax Pharma Ltd is a pharmaceutical company. The company manufactures and sells Tablets, Capsules, Ointments, and injectables. Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Paliperidone, Lacosamide, 2-Acetyl Benzo(B) Thiophene, Camphor Sulfonyl Chloride, 3-Methoxy Thiophene, Silodosin API, and others.
Contact
Rajkot-Gondal National Highway No. 27 Plot No. 20, Survey No. 52, Rajkot, GJ 360 311
T +91 2827270534
www.parmaxpharma.com opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Dec 31, 2024
Fiscal Year End
Mar 31, 2025
Employees
88

Key Metrics

Income Statement (in Mil, except ratios)
12/31/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Revenue
276.36 110.53 154.24 182.51 262.05 209.34
Revenue Growth %
109.72% -28.34% -15.49% -30.35% 25.18% 74.27%
Gross Profit
34.02 8.57 65.91 77.17 87.59 62.24
Gross Profit Margin %
12.31% 7.76% 42.73% 42.28% 33.43% 29.73%
Operating Income
-11.65 -46.51 8.29 10.49 19.47 12.29
Operating Margin %
-4.21% -42.08% 5.37% 5.75% 7.43% 5.87%
EBIT
-15.63 -51.53 4.12 6.33 14.95 7.71
EBIT Margin %
-5.66% -46.62% 2.67% 3.47% 5.70% 3.69%
EBITDA
0.52 -34.41 22.91 25.65 34.36 17.79
EBITDA Margin %
0.19% -31.13% 14.85% 14.05% 13.11% 8.50%
Net Income
-20.78 -57.79 -1.04 1.42 7.54 4.29
Net Profit Margin %
-7.52% -52.28% -0.67% 0.78% 2.88% 2.05%
Basic EPS
-24.84 -34.73 -0.28 0.38 2.02 1.15
Diluted EPS
-24.84 -34.73 -0.28 0.38 2.02 1.15
Normalized EPS
Total Dividends per Share
Balance Sheet (in Mil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Total Assets
151.57 153.31 176.13 179.74 227.28 210.64
Total Liabilities
152.56 152.60 117.57 120.17 169.10 160.00
Total Debt
57.52 59.06 53.72 51.82 58.86 52.54
Total Equity
-0.99 0.71 58.56 59.57 58.18 50.64
Cash And Cash Equivalents
0.82 0.51 1.91 8.39 25.46 17.67
Working Capital
-43.53 -34.42 3.92 -7.57 -9.06 -14.50
Shares Outstanding (Mil)
3.74 3.74 3.74
Book Value Per Share
0.19 15.65 15.92 15.55 13.54
Total Debt To Equity
83.26 0.92 0.87 1.01 1.04
Cash Flow Statement (in Mil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
23.44 -1.90 3.33 7.49 35.25 28.25
Cash From Investing Activities
-25.53 -15.87 -9.36 -15.32 -31.46 -23.99
Cash From Financing Activities
1.58 14.27 -0.44 -9.10 4.00 -2.25
Capital Expenditures
15.87 9.36 15.32 31.46 23.99
Free Cash Flow
-56.54 8.02 4.88 -2.92 -8.11
Change in Cash
-0.51 -3.50 -6.47 -16.92 7.79 2.00

Profile

There is no Key Executive Team data available.
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
No Data Available
There is no available information for this investment.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
No Data Available
There is no available information for this investment.

Ownership

There is no Ownership data available.

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top